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Although signiﬁcant strides have been made in understanding the biology of graft-versus-host disease (GVHD)
and its prevention over the last 4 decades, little is knownabout thedifferent populations of lymphocytes and the
changes in response to treatment for this condition. BMT-CTN 0302 was a randomized phase II clinical trial in
the Blood andMarrowTransplant Clinical Trials Network that assessed the efﬁcacy of combination therapywith
steroids plus pentostatin, mycophenolate mofetil, etanercept, or denileukin diftitox in patients with acute
GVHD. Patients enrolled in the study underwent blood analysis by ﬂow cytometry on days 0, 14, and 28 of
therapy to enumerate the number of total lymphocytes, T cells, B cells, and lymphocytes expressing activation
markers. Baseline total lymphocyte counts and subpopulations were similar in the 4 treatment arms.
Responding patients had a smaller decrease in total CD45þ cell count (P¼ .005) comparedwith nonresponding
patients at day 28. On univariate analysis, thosewhodeveloped chronicGVHDhad signiﬁcantly higher CD8þ cell
counts at day 14 compared with those without it (P ¼ .005). There was no signiﬁcant association between
baseline lymphocyte count and survival. On univariate analysis, among the patients with higher lymphocyte
counts at days 14 and 28, there was a trend toward better survival at day 180, although this trend did not reach
the predetermined threshold for signiﬁcance. We found no signiﬁcant differences in lymphocyte total or
subpopulation counts among the 4 treatment arms, and no notable inﬂuence on outcomes.
 2013 American Society for Blood and Marrow Transplantation.þ þINTRODUCTION
Acute graft-versus-host disease (aGVHD) is a common
complication of allogeneic blood and marrow trans-
plantation [1], characterized by an immune attack of donor
cells against host tissues, typically leading to skin rash,
diarrhea, and/or hyperbilirubinemia. The usual treatment
involves the administration of immunosuppressive agents,
particularly steroids. This treatment induces frequent clinical
responses, but ﬂares are common as steroids are tapered.
The balance between effector and regulatory T cells plays
a major role in the development of aGVHD and its resolution.
The impact of aGVHD treatment on these deﬁned lympho-
cyte populations and the association of baseline and post-
therapy phenotyping and response to this treatment are
uncertain. To better understand the most promising phar-
macologic strategies for treatment of aGVHD, knowledge of
changes in the lymphocyte regulatory and effector T cell
compartments may be important [2]. CD25 and CD69
expression on CD4þ and CD8þ T cells reﬂects their cellular
activation status and may be a useful marker for identifying
the association with aGVHD [3,4]. Clearly, CD4þCD25þ anddgments on page 485.
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12.12.003CD8 CD25 T cell phenotypes do not fully characterize
effector/regulatory phenotypes, but understanding their
relative dynamics (percentage and total numbers) in the
setting of aGVHD before and after therapy may provide
important insight into T cell immune recovery after aGVHD.
We hypothesized that agents tested in this trial (pentostatin,
denileukin diftitox, etanercept, and mycophenolate mofetil)
could have different effects on lymphocyte populations, and
that these changes could correlate with clinical outcomes.
We anticipated better response to therapy and potentially
less infection in patients who maintained higher CD4þ T cell
counts after completion of therapy. In addition, whether
counts of B cells (CD20þ) are correlated with or contribute to
the response to aGVHD therapy in these patients is unknown.
Despite the long-term use of lymphocytes in primary
therapy for aGVHD, there is little information on the changes
in different lymphocyte populations in response to steroid-
based or combination-agent aGVHD therapy. BMT-CTN
0302 was a randomized phase II clinical trial in the Blood
and Marrow Transplant Clinical Trials Network that assessed
the efﬁcacy of combination therapy with steroids plus 1 of 4
other agentsdpentostatin, mycophenolate mofetil (MMF),
etanercept, or denileukin diftitoxdbased on previous studies
demonstrating the activity of these agents in steroid-
refractory aGVHD [5-9]. Within the BMT-CTN 0302 trial,
serial blood samples were collected from study participants
and assessed for lymphocyte subsets by ﬂow cytometry. WeTransplantation.
Table 1
Day 0 Descriptive Statistics of Immunophenotyping Data
Day 0 Immunophenotyping, Cells/mL Treatment Arm All (n ¼ 120) P Valuey
Etanercept (n ¼ 30) MMF (n ¼ 29) Denileukin Diftitox (n ¼ 33) Pentostatin (n ¼ 28)
Lymphocyte CD45þ .69
Number 20 23 27 19 89
Mean (SD) 2.1 (1.4) 2.4 (1.3) 2.3 (1.2) 2.0 (1.3) 2.2 (1.2)
Median (range) 2.6 (0-4.3) 2.8 (0-4.1) 2.5 (0-3.8) 2.5 (0-3.8) 2.6 (0-4.3)
CD3þ .75
Number 30 29 33 28 120
Mean (SD) 2.3 (0.6) 2.5 (0.5) 2.4 (0.6) 2.4 (0.8) 2.4 (0.6)
Median (range) 2.4 (1.2-3.5) 2.5 (1.3-3.3) 2.4 (1.4-3.6) 2.3 (0.8-3.9) 2.4 (0.8-3.9)
CD4þ .92
Number 30 29 33 28 120
Mean (SD) 1.9 (0.8) 2.1 (0.5) 2.0 (0.6) 2.0 (0.7) 2.0 (0.6)
Median (range) 2.0 (0-3.8) 2.0 (1.0-2.8) 2.1 (0.5-3.3) 2.1 (0.7-3.5) 2.1 (0-3.8)
CD8þ .90
Number 30 29 33 28 120
Mean (SD) 2.0 (0.7) 2.1 (0.6) 2.0 (0.7) 2.0 (0.9) 2.1 (0.7)
Median (range) 2.1 (0.7-3.8) 2.0 (0.5-3.1) 2.0 (0.6-3.5) 2.1 (0-3.7) 2.1 (0-3.8)
CD25þ .73
Number 23 22 32 26 103
Mean (SD) 1.5 (0.9) 1.5 (0.6) 1.6 (0.6) 1.4 (0.7) 1.5 (0.7)
Median (range) 1.4 (0-3.9) 1.5 (0.7-2.5) 1.4 (0-2.6) 1.5 (0-2.8) 1.4 (0-3.9)
CD69þ .70
Number 21 19 24 25 89
Mean (SD) 1.5 (0.6) 1.5 (0.6) 1.6 (0.6) 1.3 (0.8) 1.5 (0.7)
Median (range) 1.6 (0-2.4) 1.5 (0.7-2.6) 1.6 (0.5-2.9) 1.5 (0-2.9) 1.6 (0-2.9)
CD20þ .48
Number 25 25 31 24 105
Mean (SD) 0.8 (0.8) 1.1 (1.0) 0.8 (0.8) 0.7 (0.9) 0.8 (0.9)
Median (range) 0.7 (0-3.1) 0.7 (0-3.3) 0.5 (0-3.3) 0.5 (0-3.4) 0.7 (0-3.4)
CD4þ/CD25þ .86
Number 23 21 30 26 100
Mean (SD) 1.4 (0.8) 1.4 (0.6) 1.3 (0.6) 1.3 (0.7) 1.3 (0.7)
Median (range) 1.3 (0-3.8) 1.5 (0-2.3) 1.3 (0-2.3) 1.4 (0-2.8) 1.4 (0-3.8)
CD4þ/CD25* .88
Number 23 21 30 26 100
Mean (SD) 1.7 (0.9) 1.8 (0.6) 1.9 (0.7) 1.9 (0.9) 1.8 (0.8)
Median (range) 1.8 (0-3.0) 1.9 (0-2.8) 2.0 (0-3.2) 2.0 (0-3.4) 1.9 (0-3.4)
* Computed as CD4þ/CD25 ¼ CD4  CD4þ/CD25þ.
y P values from the Kruskal-Wallis test.
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whether changes in lymphocyte populations were correlated
with aGVHD response, development of chronic graft-versus-
host disease (cGVHD), and survival.
MATERIALS AND METHODS
BMT-CTN 0302 and Lymphocyte Phenotyping
A total of 180 patients (median age, 50 years) were randomized to receive
methylprednisoloneat2mg/kg/dayplusetanercept,MMF,denileukindiftitox,
or pentostatin, as reported by Alousi et al. [5]. Two-thirds underwent mye-
loablative bone marrow transplantation. The graft source was peripheral
blood in61%of patients, bonemarrow in25%, andumbilical cord blood in14%;
53% of the grafts were from unrelated donors. Patientswho receivedMMF for
prophylaxis (24%) were randomized to a non-MMF arm. At randomization,
aGVHD was grade I-II in 68% and grade III-IV in 32%. One-hundred and forty
subjects had immunophenotyping data from at least 1 time point.
Complete response (CR) required resolution of all signs and symptoms
of aGVHD in all organs without intervening salvage therapies. A partial
response (PR) was deﬁned as an improvement of 1 stage in 1 or more organs
without progression in any organ. Day 28 CR rates were 26% for etanercept,
60% for MMF, 53% for denileukin diftitox, and 38% for pentostatin. Corre-
sponding 9-month overall survival (OS) rates were 47%, 64%, 49%, and 47%.
Blood was obtained at baseline on day 0 (time of study enrollment), day 14,
and day 28 of GVHD treatment; blood was collected irrespective of response
to GVHD therapy. Lymphocyte phenotyping by ﬂow cytometry gated CD45þ
cells (total lymphocytes) and enumeration of CD3þ, 4þ, 8þ, 20þ, 25þ, 69þ,
and CD4þ25þcells was performed at the transplantation center and recor-
ded as number of cells of each subset phenotype per microliter of blood.
These values were collected by the BMT-CTN data coordinating center and
analyzed in conjunction with the clinical outcomes of response and the 4
randomly assigned treatments. Immunophenotyping and outcome data
were analyzed in conjunction with a previously reported clinical study [5]
that included 180 subjects, 140 of whom had immunophenotyping datafrom at least 1 time point. The reasons formissing data included samples not
obtained (54%), participant refused (33%), participant missed clinical visits
(1%), participant died or too ill (5%), subset not assessed/performed/calcu-
lated by laboratory (5%), and not part of the ﬂow cytometry assessment (2%).
The protocol team reviewed the clinical endpoints of response (CR and PR)
at day 28 and cGVHD in all patients while still blinded to the treatment
assignment and without knowledge of the immunophenotyping data.
Statistical Analyses
The primary objective of this study was to examine how the 4 randomly
assigned agents inﬂuenced circulating lymphocyte populations, and how
these changes correlated with clinical outcomes. Clinical outcomes analyzed
wereaGVHDresponseatday28, survival at6months, andcGVHDby9months.
Lymphocyte data at each time point were compared among the treatments
using the Kruskal-Wallis test, after log10(x þ 1) transformation to induce
normality. Linearmixedmodelswere used to examine changes in lymphocyte
populations over time and evaluate their relationship to treatment.
Univariate case-control comparisons for each lymphocyte subpopulation
were performed at each time point, along with a comparison of changes in
lymphocytes from baseline using the Mann-Whitney U test. Cases were
deﬁned as patients experiencing an event (day 28 CRor CRþ PR, deathwithin
6 months, or cGVHD by 9 months), whereas controls were those alive at the
same time points without the event. Logistic regressionwas used for the day
28GVHDresponse inmultivariate analyses. Cox regressionmodelingwasused
to analyzeOS in landmarkanalyses by treating lymphocyte counts at day 14 or
day 28 as covariates in multivariate analyses. The Cox regression model was
used in landmark analysis for cGVHD by treating day 28 lymphocyte
subpopulations as covariates in multivariate analyses. Lymphocyte pop-
ulations were explored using 2 approaches: as a continuousmeasurement or
as binary covariates using themedian as a cutoff. The assigned treatment arm
andpatient characteristics that could possibly affectoutcomes, includinggraft
type, donor type, and aGVHD grade at onset, were considered in the multi-
variate analyses. Correlations among the lymphocyte population were
explored using the Pearson correlation test. All P values were 2-tailed and
J. Bolaños-Meade et al. / Biol Blood Marrow Transplant 19 (2013) 481e485 483were considered signiﬁcant at P < .01 owing to the large number of compar-
isons. Data were analyzed using SAS version 9 (SAS Institute, Cary, NC).
RESULTS
Lymphocyte Population Changes
Baseline lymphocyte total count and subpopulation counts
were similar in the 4 treatment arms (Table 1). At days 14 and
28 after treatment, modest differences in subpopulations of
CD3þ, CD4þ, CD8þ, and CD25þ were seen, whereas total
lymphocyte count (CD45þ) was similar among the treatment
arms, althoughnodifferenceswere statistically signiﬁcant at P
< .01 (Tables 2 and 3). Linear mixed models produced similar
modest differences in these lymphocyte subpopulations,
whichwerenot statistically signiﬁcant atP< .01.No signiﬁcant
changes in lymphocytes with activation markers (CD25þ and
CD69þ), or in lymphocytes associated with regulatory T cell
subsets (CD4þ25þ), or total B cells (CD20þ) were noted after
therapy or among the 4 treatment cohorts.
Cell Populations and GVHD Response
Univariate analysis identiﬁed a moderately strong associ-
ation between declining lymphocyte count and GVHD
response. Patients responding (CR/PR) at day 28 had a smaller
decrease in total CD45þ cell count at day 28 compared with
nonresponding patients (P ¼ .005). On multivariate logistic
regression modeling of GVHD response, after adjusting for
day 14 GVHD response, there was a signiﬁcant effect of
changes in total lymphocyte count from baseline to day 28
(odds ratio, 4.63; 95% conﬁdence interval [CI], 1.41-15.20; P¼
.012) with greater drops in lymphocyte count associatedwithTable 2
Day 14 Descriptive Statistics of Immunophenotyping Data
Day 14 Immunophenotyping, Cells/mL Treatment Arm
Etanercept (n ¼ 23) MMF (n ¼ 25) D
Lymphocyte CD45þ
Number 13 22 1
Mean (SD) 2.1 (1.5) 2.5 (1.3) 1
Median (range) 24 (0-4.3) 2.6 (0-4.6) 2
CD3þ
Number 23 25 2
Mean (SD) 2.0 (0.9) 2.6 (0.5) 2
Median (range) 2.1 (0-3.8) 2.5 (1.8-4.0) 2
CD4þ
Number 22 25 2
Mean (SD) 1.6 (0.8) 2.0 (0.7) 1
Median (range) 1.7 (0-3.2) 2.2 (0.7-3.1) 2
CD8þ
Number 22 25 2
Mean (SD) 1.8 (0.8) 2.2 (0.7) 1
Median (range) 2.0 (0-3.4) 2.3 (0.3-3.7) 1
CD25þ
Number 19 18 2
Mean (SD) 1.1 (0.6) 1.4 (0.7) 1
Median (range) 1.3 (0-2.0) 1.6 (0-2.4) 1
CD69þ
Number 19 17 1
Mean (SD) 1.0 (0.8) 1.4 (0.7) 1
Median (range) 1.0 (0-3.0) 1.4 (0-2.9) 1
CD20þ
Number 19 19 2
Mean (SD) 0.9 (0.8) 0.9 (0.9) 1
Median (range) 0.8 (0-2.8) 0.8 (0-2.6) 0
CD4þ/CD25þ
Number 19 18 2
Mean (SD) 1.1 (0.6) 1.4 (0.7) 1
Median (range) 1.2 (0-1.9) 1.6 (0-2.5) 1
CD4þ/CD25
Number 19 18 2
Mean (SD) 1.5 (0.8) 1.7 (0.8) 1
Median (range) 1.4 (0-3.2) 1.9 (0-2.9) 2signiﬁcantly lower likelihood of response. Figure 1 presents
a boxplot of CD45þ cell counts in day 28 GVHD responders
versus nonresponders. No other lymphoid subsets were
associated with GVHD response (Supplemental Table 1).
Cell Populations and Chronic GVHD
On univariate analysis, patients with a higher CD8þ count
at day 14 had a greater frequency of cGVHD, and patients
who developed cGVHD had signiﬁcantly higher CD8þ cell
counts at day 14 compared with those without cGVHD
(P ¼ .005). In Cox regression modeling of cGVHD, the hazard
ratio for risk of cGVHD for patients with CD8þ values above
the median (100 cells/mL) compared with those with lower
CD8þ values was 1.88 (95% CI, 0.97-3.66; P ¼ .06). No other
baseline risk factor demonstrated a signiﬁcant association
with cGVHD. The cumulative incidence of cGVHD by CD8þ
value is shown in Figure 2. No other lymphoid subsets were
associated with risk of cGVHD (Supplemental Table 2).
Lymphocyte Populations and Survival
There was no signiﬁcant association between baseline
lymphocyte count and survival, relapse, or CMV infection.
Univariate analysis detected a trend toward better survival at
day 180 in patients with elevated lymphocyte counts at days
14 and 28, although this did not reach the predetermined
threshold for signiﬁcance (P < .01). Cox regression modeling
of OS, after adjusting for GVHD response, revealed a signiﬁ-
cant favorable effect of total lymphocyte count above versus
below the median at day 14 (hazard ratio, 2.90; 95% CI,
1.42-5.92; P¼ .004), but not at day 28 (P¼ .53). Kaplan-MeierAll (n ¼ 97) P Value
enileukin Diftitox (n ¼ 25) Pentostatin (n ¼ 24)
.32
9 21 75
.9 (1.3) 1.9 (1.2) 21 (1.3)
.3 (0-3.3) 2.2 (0-3.7) 2.4 (0-4.6)
.04
5 23 96
.2 (0.8) 2.1 (0.7) 2.2 (0.7)
.2 (0-3.5) 2.1 (0.3-2.9) 2.3 (0-4.0)
.13
5 24 96
.9 (0.7) 1.7 (0.7) 1.8 (0.7)
.0 (0-3.1) 1.6 (0-3.5) 1.8 (0-3.5)
.22
5 24 96
.9 (0.8) 1.9 (0.9) 1.9 (0.8)
.8 (0.3-3.3) 2.0 (0-3.6) 2.0 (0-3.7)
.02
1 20 78
.4 (0.6) 1.0 (0.5) 1.2 (0.6)
.6 (0.3-2.2) 1.1 (0-1.9) 1.3 (0-2.4)
.12
8 22 76
.4 (0.6) 1.1 (0.6) 1.2 (0.7)
.3 (0.3-2.4) 1.2 (0-2.3) 1.2 (0-3.0)
.39
2 22 82
.0 (0.8) 0.6 (0.5) 0.8 (0.8)
.9 (0-2.8) 0.5 (0-1.6) 0.8 (0-2.8)
.12
1 21 79
.2 (0.7) 1.0 (0.6) 1.2 (0.7)
.3 (0-2.2) 1.0 (0-2.3) 1.2 (0-2.5)
.37
1 21 79
.9 (0.7) 1.6 (0.7) 1.7 (0.8)
.0 (0-3.1) 1.6 (0-3.5) 1.7 (0-3.5)
Table 3
Day 28 Descriptive Statistics of Immunophenotyping Data
Day 28 Immunophenotyping, Cells/mL Treatment Arm All (n ¼ 108) P Value
Etanercept (n ¼ 25) MMF (n ¼ 31) Denileukin Diftitox (n ¼ 28) Pentostatin (n ¼ 24)
Lymphocyte CD45þ .16
Number 16 23 23 21 83
Mean (SD) 1.7 (1.3) 2.4 (1.3) 2.0 (1.2) 1.8 (1.2) 2.0 (1.2)
Median (range) 1.8 (0-4.1) 2.6 (0-4.6) 2.4 (0-2.5) 2.1 (0-3.6) 2.3 (0-4.6)
CD3þ .20
Number 25 31 28 24 108
Mean (SD) 2.2 (0.6) 2.3 (0.6) 2.2 (0.7) 1.9 (0.6) 2.2 (0.7)
Median (range) 2.2 (1.0-3.9) 2.3 (0.9-3.5) 2.2 (0.3-3.5) 1.9 (0-2.7) 2.2 (0-3.9)
CD4þ .04
Number 24 30 27 24 105
Mean (SD) 1.8 (0.6) 1.9 (0.6) 1.8 (0.6) 1.4 (0.6) 1.7 (0.6)
Median (range) 1.6 (0.5-3.1) 2.0 (0.7-3.1) 1.8 (0.5-3.1) 1.5 (0-2.5) 1.7 (0-3.1)
CD8þ .04
Number 24 30 27 24 105
Mean (SD) 2.0 (0.7) 2.1 (0.6) 1.9 (0.8) 1.5 (0.8) 1.9 (0.7)
Median (range) 2.0 (0.6-3.6) 2.0 (0.7-3.8) 1.9 (0.5-3.5) 1.4 (0-2.6) 1.9 (0-3.8)
CD25þ .37
Number 19 22 24 22 87
Mean (SD) 1.3 (0.8) 1.3 (0.6) 1.3 (0.6) 1.0 (0.6) 1.2 (0.6)
Median (range) 1.4 (0-3.6) 1.4 (0-2.6) 1.4 (0.3-2.2) 1.1 (0-2.0) 1.3 (0-3.6)
CD69þ .25
Number 19 22 19 22 82
Mean (SD) 1.3 (0.9) 1.3 (0.6) 1.3 (0.6) 1.0 (0.6) 1.2 (0.7)
Median (range) 1.4 (0-3.6) 1.4 (0-2.6) 1.4 (0-2.5) 1.1 (0-1.9) 1.2 (0-3.6)
CD20þ .21
Number 20 23 24 21 88
Mean (SD) 1.0 (0.8) 0.7 (0.8) 0.8 (0.8) 0.5 (0.5) 0.7 (0.8)
Median (range) 1.0 (0-3.1) 0.5 (0-2.6) 0.5 (0-2.7) 0.3 (0-1.3) 0.5 (0-3.1)
CD4þ/CD25þ .06
Number 19 22 23 23 87
Mean (SD) 1.4 (0.7) 1.2 (0.7) 1.1 (0.7) 0.8 (0.6) 1.1 (0.7)
Median (range) 1.4 (0-3.6) 1.2 (0-2.5) 1.4 (0-2.2) 0.7 (0-1.8) 1.1 (0-3.6)
CD4þ/CD25 .19
Number 19 22 23 23 87
Mean (SD) 1.5 (0.7) 1.7 (0.7) 1.7 (0.7) 1.1 (0.8) 1.5 (0.8)
Median (range) 1.4 (0-2.6) 1.6 (0.5-3.0) 1.6 (0-3.1) 1.3 (0-2.4) 1.5 (0-3.1)
J. Bolaños-Meade et al. / Biol Blood Marrow Transplant 19 (2013) 481e485484estimates of OS based on day 14 CD45þ cell count above or
below the median value (200 cells/mL) are shown in
Figure 3. It appears that higher CD69þ cell counts at day
14 (P ¼ .009) and day 28 (P ¼ .05) may be correlated
with better survival. No other lymphocyte subpopulations
were associated with survival (Supplemental Table 3).Figure 1. Boxplot of CD45þ cell counts for day 28 GVHD responders versus
nonresponders. The P value reﬂects the CD45þ cell count change frombaseline to
day 28 posttreatment for day 28 responders versus nonresponders. Data are on
a log scale, with a 1-unit change equal toþ10 and a 2-unit change equal toþ100.DISCUSSION
We examined the inﬂuence of 4 different, randomly
assigned GVHD therapies to cause distinct changes in lympho-
cyte populations that would help understand and potentially
predict the observed differences in therapeutic effects of each
treatment. The 4 treatment arms demonstrated no signiﬁcant
differences in total lymphocyte or lymphocyte subpopulation
counts, and treatment had no notable inﬂuence on outcomes.
We performed a detailed and prospective characterization
of lymphoid populations through the initial course of aGVHD
therapy with steroids plus 1 of the 4 novel agents. Although
we found no signiﬁcant differences in lymphocyte pop-
ulationsduring theﬁrst 28days among the4 studygroups,we
did ﬁnd an association between higher CD45þ lymphocyte
counts at day 28 after initiation of therapy and response, and
an apparent trend toward an association between higher
CD8þ counts early after treatment and the subsequent
development of cGVHD [10]. The results of Grogan et al. [10]
suggest that CD8þ T cells in patients with cGVHD are charac-
terized by increased activation and proliferation, and this cell
populationmay be present early during an episode of aGVHD.
We also observed a trend toward better survival in
patients with elevated CD45þ lymphocyte populations at day
14 and day 28. These results are intriguing, and suggest that
preservation of lymphocyte populations after aGVHD
therapy is crucial for immune recovery and protection
against subsequent infections.
This study has some limitations. The number of patients
was modest, and our data were incomplete at some time
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Figure 2. Cumulative incidence of cGVHD by day 14 CD8þ lymphocyte count.
The P value reﬂects a comparison of the cumulative incidence of cGVHD for
patients with higher CD8þ counts (cells 100/mL; n ¼ 50) at day 14 versus
patients with lower CD8þ counts (cells <100/mL; n ¼ 46) at day 14.
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drugs (MMF and pentostatin as lymphoid metabolic inhibi-
tors, etanercept as a TNF-a blocker, and denileukin diftitox as
a CD25þ celledirected lytic immunotoxin), differing effects
on circulating lymphoid subsets might have been predicted.
Somewhat surprisingly, all the 4 study drugs caused similar
changes in counts of both total lymphocytes and lymphocyte
subpopulations. This is likely inﬂuenced and confounded by
the fact that all 4 of our study cohorts were treated concur-
rently with high-dose corticosteroids. In addition, our
phenotypic analysis was limited and insufﬁcient to accu-
rately characterize the functionality of T cell subsets,
reﬂecting the feasibility of conducting multicolor ﬂow
cytometry analysis of specimens in the multi-institutional
setting.
Although CD4þCD25þ and CD8þCD25þ T cell phenotypes
are useful in identifying the association with GVHD [3,4],O
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Figure 3. OS by day 14 CD45þ lymphocyte count. The P value reﬂects
a comparison of OS probability for patients with higher CD45þ cell counts
(cells 200/mL; n ¼ 41) at day 14 versus patients with lower CD45þ cell counts
(cells <200/mL; n ¼ 34) at day 14.they do not fully characterize effector/regulatory pheno-
types. The addition of intracellular staining to forkhead box
P3 (FoxP3) might have aided the assessment of regulatory T
cells; however, some studies have reported decreased
numbers of CD4þCD25þFoxp3þ T cells in patients with
GVHD, whereas others have not [11,12]. On the other hand,
our ﬁndings are consistent with those reported by Prze-
piorka et al. [13], which also showed that phenotypic
changes in T cell subpopulations do not predict response to
daclizumab in patients with active GVHD.
Although this detailed examination of lymphocyte
subpopulations did not clarify the mechanism of response or
why the 4 study agents led to different clinical outcomes, we
suggest that future studies of GVHD therapy include ongoing
evaluation of lymphocyte, serum, or tissue biologic markers
to uncover important details of the immunobiology that can
help further reﬁne clinical treatment approaches.
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